Safety profile of Tiotropium + Olodaterol used as maintenance treatment in COPD patients in Taiwan: a non-interventional study based on the Taiwan National Health Insurance (NHI) data (1237-0109)

Study identification

• EU PAS number:
  EUPAS47368
• Study ID:
  49764
• Official title and acronym:
  Safety profile of Tiotropium + Olodaterol used as maintenance treatment in COPD patients in Taiwan: a non-interventional study based on the Taiwan National Health Insurance (NHI) data (1237-0109)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  To estimate the incidence of safety outcomes in patients with COPD who initiated Tiotropium / Olodaterol (Tio/Olo)
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned: 17/06/2021

Actual: 17/06/2021

Study start date

Planned: 15/08/2022

Actual: 30/09/2022

Date of final study report

Planned: 23/06/2023

Actual: 09/06/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim (China) Investment Co., Ltd

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable